Apple Tree Partners. a pioneer in life sciences venture capital, is developing the next generation of transformative biotechnology companies.
We create science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines.
We provide flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises.
We invest in our companies from seed stage through IPO and beyond, and we support our management teams in strategic transactions and synergistic business combinations.
Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering
Stoke Therapeutics Announces Proposed Public Offering
Nereid Therapeutics Launches: ATP $50M Series A NewCo Co-Founded with Brangwynne, Pioneer of Biomolecular Condensates Field
Akero Therapeutics Reports Third Quarter 2020 Financial Results
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates